

Martínez Pérez S, Llinares Esquerdo M, García Iranzo E, García Monsalve A, Matoses Chirivella C, Navarro Ruiz A.
Hospital General Universitario de Elche. Pharmacy Department.

OBJECTIVES: To describe the use of a new therapy based on PRGF eye-drops and the baseline and pathological characteristics of the subjects with ocular surface disease.

METHODS:

- ✓ Retrospective observational study (September 2016-2017).
- ✓ Patients who were treated with PRGF and collected it at the Outpatient Pharmaceutical Care unit of the hospital pharmacy.
- ✓ The PRGF eye-drops was manufactured in the Pharmacy Service with a commercial kit.
- ✓ The demographics and clinical parameters were collected from the medical history: age, gender, number of patients, the pathology and the efficacy of the treatment.

RESULTS:


14 Patients
(5 women; 17 eyes)

Mean age:
66 years
(53-81)

Average treatment
duration with PRGF
5,7 months

21 dispensations
(2 dispensations / patient)

Distribution of pathologies:



Effectiveness of PRGF:

- ✓ 12 patients: resolution of the ocular disease.
- ✗ 2 patients: not improvement of the symptoms.

Security of PRGF:

During the period of the study, did not detected any adverse event related to the PRGF eye-drops.

DISCUSSION AND CONCLUSIONS:

The study showed that the use of PRGF eye-drops is effective to treat ocular surface diseases. Regarding tolerance for PRGF, it seems safe for the patients.